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association between drug and lab outcomes for the cohort matched on demo-
graphic and comorbid information only (p0.001). There was no significant asso-
ciation in the cohort matched on biomarkers plus comorbid and demographic
variables (p0.414). CONCLUSIONS: PSM using administrative claims alone left
considerable channeling bias in the sample, and erroneous conclusions were
drawn from subsequent GMM analysis. Inclusion of biomarkers in the PSM re-
moved this bias and yielded non-significant GMM results. Administrative claims
data without biomarkers may not be sufficient for conducting PSM.
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IMPACT OF VAGUS NERVE STIMULATION (VNS) THERAPY ON CLINICAL
OUTCOMES AND COSTS IN MEDICAID PATIENTS WITH DRUG-RESISTANT
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OBJECTIVES: This study evaluated the benefits of VNS Therapy on health resource
utilization (HRU), epilepsy-related comorbidities, and costs over time in drug-re-
sistant epilepsy patients in a clinical practice setting. METHODS: An open-cohort
pre-post analysis was conducted using Medicaid data from FL, NJ, IA, MO, and KS
(January 1997-June 2009). Patients had1 neurologist visit with epilepsy diagnosis
(ICD-9 345.xx, 780.3, or 780.39), 1 procedure for VNS Therapy implantation, 1
anti-epileptic drug (AED), 6 months of pre- and post-VNS Therapy continuous
enrollment. The 6-months precedingVNSTherapy implantationwas designated as
Pre-VNS Therapy period. Post-VNS Therapy periodwas designated from the date of
VNS Therapy implantation until removal of device, death, or Medicaid disenroll-
ment. Univariate and multivariate Poisson regressions (incidence rate ratios [IRR]
and 95% confidence intervals [CI]) compared HRU and epilepsy-related comorbidi-
ties and GLM models estimated cost differences between the pre- and post-VNS
Therapy periods. Costs were adjusted to $2009 using medical care component of
the consumer price index. RESULTS:Of the 1655 patients, mean age was 29.4 years
and 51.4% were males. Compared to Pre-VNS Therapy period the incidence of
hospitalizations and emergency room (ER) visits decreased over time during Post-
VNS Therapy period (Trend: 0.9238, p.0001 and Trend: 0.9526, p.0001, respec-
tively). Generalized tonic-clonic seizure events showed a decreasing trend during
Post-VNS Therapy period than Pre-VNS Therapy period (adjusted IRR: 1.23 [CI:
1.03-1.46] in Q1 to 0.17 [CI: 0.11-0.27] in Q12). During Post-VNS Therapy period,
average total health care costs decreased from $42,540 (Q1) to $14,316 (Q12). After
1.5 years, cost savings in Post-VNSTherapy period started to outweigh total costs of
VNS Therapy device and implantation procedures. CONCLUSIONS: To conclude,
VNS Therapy is associated with decreased HRU and common epilepsy-related co-
morbidities, such as hospitalizations, ER visits and generalized tonic-clonic seizure
events, resulting in net cost savings for public payers after about 1.5 years.
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A META-ANALYSIS OF BIOMARKERS AND DIAGNOSTIC IMAGING IN
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OBJECTIVES:MildAlzheimer’sDisease (AD) is oftendifficult todifferentiate frommild
cognitive impairment (MCI) or non-ADdementias. Amultitude of diagnostic biomark-
ers and advanced imaging strategies have been developed to aid in the diagnosis and
management of AD. Examples of biomarkers include total tau, phosphorylated tau
(Ptau), and the 42 amino acid form of beta-amyloid (A1-42) and imaging strategies
include MRI, FDG-PET, SPECT and CT. We sought to systematically review and meta-
analyze the published evidence on key test characteristics of major diagnostic strate-
gies in AD. METHODS: A systematic review was undertaken to locate all studies of
biomarkers or diagnostic imaging for AD published in English from January 1990 to
March 2010. Meta-analysis was performed using a bivariate mixed-effects binary re-
gression model. We calculated sensitivity (SN), specificity (SP) and area under the
receiver operating curves (AUROC), with confidence and prediction contours in order
to formulate best estimates of SN and SP of commonly used diagnostic tests for AD.
RESULTS:Of 1,840unique studies identified, 119 presentedprimary data sufficient for
analysis. For each diagnostic method, SN and SP were calculated against non-de-
mented controls, non-AD dementias with andwithout MCI, if available. Compared to
non-demented controls, FDG-PET demonstrated the highest AUROC (0.96), with 90%
SN (95%CI 84% to 94%) and 89% SP (95% CI 81% to 94%). FDG-PET also wasmost accu-
rate in discriminating AD from demented controls (including MCI) with AUROC 0.91,
and 92% SN (95%CI 84% to 96%) and 78% SP (95% CI 69% to 85%). For discrimination of
AD from non-AD dementias (excluding MCI), CSF Ptau and SPECT produced identical
AUROC (0.86)with 79%and86%SNand80%and81%SP, respectively.CONCLUSIONS:
Diagnostic strategies for AD show wide variation in test characteristics and some
show promise for clinical practice.
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OBJECTIVES: Despite well conducted treatment, schizophrenic patients often re-
main symptomatic. Although multiple studies studied resistant patients, no data
are available on partial responders (PR). The purpose of this study is to compare
clinical, quality of life (QoL), cost of PR versus non symptomatic patients (full
respondersFR), and to assess the evolution of PR. METHODS: An analysis was
performed based on a sample of patients in France and UK followed prospectively
over 2 years. At baseline, resistant as well as acute exacerbated patients were
excluded. Symptomatic patients were defined according to 3 clinical criteria: CGI
score 4 and PANSS score 60 (with 3 items 4). Evolution was assessed over the
2 years period. The following information was collected using standardized vali-
dated instruments: psychotic symptoms, depression, side effects, compliance,
functioning, specific and generic QoL, resource utilisation. RESULTS: 93 (19%) pa-
tients were identified as PR and 284 (59%) as FR out of 484 patients. The population
of PR was well discriminated at baseline period when compared to FR. Clinical
symptoms including depression and side effects, compliance, functioning, QoL are
more severe in PR than in FR. Cost of management of PR appears significantly
higher than FR. Patients identified as PR remained PR over the 2 years period. The
change of prescription including switch, dosage increase or therapy augmentation
is similar between PR and FR. CONCLUSIONS: The PR is a stable population over-
time with higher clinical burden and increased management cost compared to FR.
The lack of specific treatment pattern raises the issue of the need for specific
disease management strategy of PR and related assessment of such intervention.
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PERCEPTION OF IRON DEFICIENCY IN CLINICAL PRACTICES:
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OBJECTIVES: To assess the perception of iron deficiency and describe themanage-
ment of iron deficiency in clinical practices.METHODS: Physicians were randomly
selected from a professional directory. They reported in a questionnaire the esti-
mated frequency of iron deficiency and anemia among their patients, the biological
exams performed for iron deficiency diagnosis and the conditions of use of intra-
venous iron. The survey analysis was performed on 358 questionnaires (return
rate: 12%) from physicians of different areas of expertise (anesthesia, intensive
care, surgery, n67; gynecology, obstetrics, n122; oncology, hematology, radio-
therapy, n39; hepato-gastroenterology, internal medicine, geriatrics, rheumatol-
ogy, n130). RESULTS:Out of 86% (309/358) of the physicians reported cases of iron
deficiency. For 63% of them (223/358), the frequency of anemia among their pa-
tients wasmore than 10%. Survey responders were 25% (89/358) to report that they
systematically explored iron deficiency and 61% (217/358) only if anemia had been
previously diagnosed. Severe iron deficiency, is treated with oral iron in 75% (269/
358), 39% (141/358) with intravenous iron and 20% (70/358) with transfusion. For
70% of the physicians who prescribe intravenous iron (148/213) the limit threshold
of hemoglobin for prescription of intravenous iron of 8 g/dL (median). In contrast
with hemoglobin level, serum ferritin and transferrin saturation,were infrequently
performed (15% [31/213] and 5% [11/213], respectively). The use of erythropoiesis-
stimulating agents was reported by 44% (156/358) of physicians with systematic
iron supplementation for only 47% (74/156) of them. CONCLUSIONS: One of the
main results of this survey is the apparent equation between iron deficiency and
anemia in many physicians. Thus, most physicians report that intravenous iron is
used when hemoglobin is at a median value  8 g/dL, Therefore, iron deficiency is
considered only within a context of severe anemia for many physicians.
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OBJECTIVES: This pilot studywas to evaluate and compare drug eluting stent (DES)
and bare metal stent (BMS) in 1) clinical outcome; 2) humanistic outcome; and 3)
economic outcome, in patients undergoing percutaneous coronary intervention
(PCI). METHODS: All patients undergo PCI in Prince of Wales Hospital during Au-
gust 1 to October 31, 2009 were recruited. Clinical outcome was measured by the
occurrence of major adverse cardiac events (MACE), which is defined as cardiac
death, non-fatal MI and target lesion revascularization. An EQ-5D questionnaire
was used tomeasure the baseline quality of life before the stent placement, and six
months post PCI. Procedural cost including the instruments, medications and hos-
pitalization, as well as all cardiac related follow-up for the first six months was
recorded. Cost to reduce one MACE (ICER) and cost to gain one quality-adjusted
life-year (QALY) was calculated to assess the cost-effectiveness of DES. RESULTS:A
total of 50 patients (n22 and n28 for DES and BMS respectively) were enrolled
into our study. MACE in 6 month was 5% in DES (n1) versus 7% (n2) in BMS
respectively (p0.701). In DES group, the utility score showed significant improve-
ment in six months than baseline (0.92, IQR 0.80–1.00 vs. 0.69, IQR 0.22–0.77,
p0.001), while there were no significant improvement for BMS group (0.87, IQR
0.73–1.00 vs. 0.81, IQR 0.66–1.00, p0.337). ICER calculated was HKD$17,112 and
cost per QALY gained was HKD$142,600. six-month total medical cost was similar,
HKD$92,44058,566 for DES (median$74231) versus $95,22364,301 for BMS (me-
dian$76475) respectively, p0.875, the higher procedural cost of DES group was
balanced by lower follow-up and hospitalization cost, when compared with BMS
group.CONCLUSIONS:Thequality of life of patient underwent placementwithDES
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improved significantly and the use of DES were shown to be cost-effective. The
6-month total medical cost for DES and BMS were similar.
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READMISSION RATES AND COSTS ASSOCIATED WITH FIBRIN SEALANT USE
AMONG PATIENTS UNDERGOING ORTHOPEDIC SURGERY
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OBJECTIVES: Payers and hospital administrators are increasingly concerned about
readmission rates in surgical patients. We sought to examine the readmission
rates and hospital costs associated with EVICEL fibrin sealant (all-human formula-
tion), versus VITAGEL fibrin sealant (with bovine thrombin), or no adjunct hemo-
stat use for patients undergoing inpatient joint replacement surgeries.METHODS:
A retrospective analysis was conducted using Premier administrative data from
over 500UShospitals. Hospitalized patients (18 years)whounderwent orthopedic
surgery and received EVICEL, VITAGEL or no hemostat during surgery between
January 1, 2009 and November 30, 2009 were identified. A 1:1 (EVICEL:VITAGEL) and
1:3 (EVICEL: no hemostat) match was conducted using surgery type and propensity
scores of receiving EVICEL, based on patient and hospital characteristics via a
logistic regression model. The outcomes included 30-day all-cause readmission
rates and total index hospital costs. Differences in readmission rates were ana-
lyzed using conditional logistic regression. A generalized linear model with log-
link/gamma distribution was used for analyzing differences in total costs.
RESULTS: A total of 316 patients were identified (158 per cohort) for the EVICEL
versus VITAGEL and 1,808 patients for EVICEL (n452) versus no hemostat
(n1,356) analysis. Patients in the VITAGEL cohort were 6.8 times more likely to be
readmitted to the hospital compared to the EVICEL cohort (12.7% vs 3.8%; OR6.81,
95%CI 1.62, 28.66). Patients in the no hemostat cohort were 1.6 timesmore likely to
be readmitted compared to the EVICEL cohort. Total index hospital cost was lower
for the EVICEL cohort ($16,704) compared to VITAGEL cohort ($18,192 p0.001) on
average. The EVICEL cohort ($17,387) had similar total costs compared to no ad-
junct hemostat ($17,389) cohort. CONCLUSIONS: Readmission presents significant
costs and has been added to hospital quality measures. In this study, EVICEL was
associated with lower readmission rates compared to VITAGEL or no adjunct he-
mostat use in inpatient joint replacement surgeries.
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DIFFERENCES IN OUTCOMES MEASURES OF DIABETES PATIENTS USING AN
INSULIN DEVICE AND A CONVENTIONAL HUMAN INSULIN VIAL/SYRINGE
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OBJECTIVES: To compare the main outcomes differences including clinical events,
health care utilization and costs of patients using an insulin device for diabetes versus
patients using the conventional human insulin vial/syringe.METHODS: Using a ret-
rospective analysis of health insurance claims data between the years 2003 and 2008,
we identified patients with a diagnosis of diabetes and then divided them into an
insulindevice cohort andahuman insulinvial/syringe cohort, basedon their prescrip-
tion fills. Patients’ demographics, health care visits and costs were compared using
Chi-square testing and standardized differences. The 12-month follow-up clinical
event rates, health care facility use and costs for those patients were compared. Risk
adjustment was performed using the propensity score matching method with the
ProbChoice™algorithm.RESULTS:A total of 12,400 eligible patientswere identifiedas
using insulin for diabetes: 1,236 (9.97%) received the insulin device and 11,164 (90.03%)
received the insulin vial/syringe. Compared with patients who received the conven-
tionalhuman insulinvial/syringe, patients in the insulindevice groupwere likely tobe
younger, live in the Midwest of the United States, and have type I diabetes. Although
there were no significant differences in hypoglycemic events after risk adjustment,
patients in the insulin device group had significantly fewer cases of cerebrovascular
disease (4.14% vs. 9.12% p0.0055), congestive heart failure (7.18% vs. 12.15%
p0.0267) and chronic obstructive pulmonarydisease (4.70%vs. 10.50%p0.0039), but
more cases of dyslipidemia (68.51% vs. 54.42% p0.0002). Although the outpatient
costs for office visits ($1888 vs. $1895 p0.0257) were lower for patients on the insulin
device, their prescription costs ($5489 vs. $4635 p0.0001) were higher. The overall
risk-adjusted healthcare costs did not differ ($14,231 vs. $18,096 p0.1160) between
the two groups. CONCLUSIONS: Without significant addition to the costs, insulin
administration with the device is associated with fewer clinical events.
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POSITRON EMISSION TOMOGRAPHY SCREENING FOR LUNG CANCER: A
SYSTEMATIC REVIEW
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OBJECTIVES: There is no established effective lung cancer screening modality.
Positron Emission Tomography (PET) is helpful in lung cancer disease extent eval-
uation. The objective of our study is to evaluate the role of PET in lung cancer
screening via systematic review.METHODS: Using a strategy similar to a previous
computed tomography (CT) lung cancer screening systematic review [Black et al.
Thorax 2007;62:131–138], we searched for primary studies focusing on PET screen-
ing for lung cancer using the following keywords “(lung cancer) AND (positron
emission tomography) AND ((screen) OR (screening))” in Pubmed® on Nov 30th,
2010. Two reviewers (Chien C.R. & Wang H.N) reviewed all the identified studies
independently to find out studies compatible with our inclusion/exclusion criteria.
Further discussion with 3rd reviewer (Kao C.H.) was taken to reach conclusion
when there was any disagreement among the reviewers. Manual searching for
relevant studies was also performed from the included studies. We restricted our
analysis to non-overlapped studies published since 2000 and in English. RESULTS:
Among the identified studies (n2733), 239 studies were published before 2000,
2440 studies were excluded due to irrelevant titles and keywords, and another 34
studies were excluded after reviewing the abstracts. Full paper evaluation led to
further exclusion of 11 studies, and manual search led to inclusion of 2 additional
studies, leaving 11 studies for analysis. No studies evaluated the efficacy of primary
PET screening specific for lung cancer. Eight studies focused on primary PET
screening for cancer, and three studies reported finding in lung cancer CT screen-
ing programswith selective PET.CONCLUSIONS:The role of primary PET screening
for lung cancer remains unknown. PET has the potential to be used as a screening
modality not specific for lung cancer and as a selective modality in combination
with CT for lung cancer screening. [1] Black et al. Thorax 2007; 62:131-138
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ESTIMATION OF QUALITY-ADJUSTED LIFE EXPECTANCY AND LOSS OF
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MECHANICAL VENTILATION: A POPULATION-BASED STUDY DURING 1998-
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OBJECTIVES:Thequality-adjusted life expectancy (QALE) and loss of quality-adjusted
life expectancy (loss of QALE) in patients under prolonged mechanical ventilation
(PMV) stratified by different underlying diseaseswere determined.METHODS:A sim-
ple randomsample of all 171, 635 patientswhowere performed continualmechanical
ventilation formore than21daysduring the1997-2007periods inTaiwan left us 50,481
subjects. After stratifying the patients according to specific diagnoses, we performed
latent class analysis (LCA) to categorize PMVpatientswithmultiple comorbidities into
several clustered groups. The survival functions were estimated for each group with
Kaplan-Meier method and extrapolated to 300months to obtain the life expectancies
through a semi-parametricmethod. The resultswere adjustedwith a utilitymeasure-
ment of quality of life to estimate the QALE (quality-adjusted life expectancies). Fur-
ther, we compared the age-, gender-matched reference populations to calculate the
loss of QALE.RESULTS: TheQALE of PMVpatientswith chronic renal failurewere 0.42
and 0.19 quality-adjusted life years (QALY) for consciousness clear versus unclear
states, respectively; those of patients with cancer were 0.48 and 0.22, respectively;
those of patients with Parkinson’s disease were 0.62 and 0.27, respectively; those of
patients with liver cirrhosis were 0.98 and 0.43 respectively; those of patients with
strokewere1.03and0.46 respectively; thoseofpatientswithdegenerativeneurological
diseases were 1.47and 0.64 respectively; those of patients with injuries and poisoning
were1.81 and 0.78 respectively. The LCA classified cases with multiple comorbidities
into several categories, of which therewas a consistent trend of decrease in QALE and
loss of QALE as people grow old. CONCLUSIONS: The results could hopefully reduce
thegapbetweenpatients’ familiesandhealthcareprovidersandassist theclinical and
health policy decisions.
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SCREENING TREATMENT AND CONTROL OF HYPERTENSION IN DIABETIC
PATIENTS USING OUTPATIENT VISIT DATA
Surbhi S, ML Mackey
St. John’s University, Queens, NY, USA
OBJECTIVES: Blood pressure control is a great challenge in the diabetic patient
population since the blood pressure target is lower, 130/80, as compared to
140/90 in general population. The objective of this study was to examine the rate
and the association of patient characteristics (demographic, access to health care
and clinical factors) and practice characteristics with hypertension screening,
treatment and control in diabetic population. METHODS: National Ambulatory
Medical Care Survey and the National Hospital Ambulatory Medical Care Survey
2006 were used to analyze outpatient visits made by adults18 years and older
diagnosed with diabetes. Descriptive analysis was done to find the rate and binary
logistic regression was carried out to find the predictors. Statistical significance
was set at alpha of 0.05. RESULTS: Hypertension screening, treatment and control
rate was 66.9%, 53.1% and 28.4% in diabetic patients. The odds of not getting
screenedwere visits other than primary care physician (OR7.52), with no diagnostic
tests (OR6.63), having no comorbidities (OR3.64), non obese (OR1.72) and increasing
age (OR2.03, OR2.35, OR2.72). Odds of not being treated were settings located in
south geographic region (OR1.29), provider other than primary care physician
(OR2.02), hospital setting (OR1.28), no diagnostic tests (OR1.97) and having no co
morbidities (OR1.558). Odds of not having blood pressure control were greater for
black race (OR 1.75), patients with no past visits (OR 1.79), obese (OR 1.37) and
having no co morbidities (OR 1.40). CONCLUSIONS: The study found that although
more than 50% of the diabetic patients were screened and treated, blood pressure
control was found in only one third of the population. Both the patient factors;
demographic, access to health care, clinical factors and practice characteristics
were responsible for poor quality of care (hypertension screening and treatment)
and poor outcome (blood pressure control).
Medical Device/Diagnostics – Cost Studies
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IDENTIFYING POTENTIAL DRIVERS OF COST SAVINGS WITH INSULIN
ADMINISTRATION DEVICES IN TYPE-2 DIABETES IN THE UNITED STATES
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